NCT00072150 2013-06-05Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell CarcinomaNational Cancer Institute (NCI)Phase 2 Completed40 enrolled